BeyondSpring Inc., a clinical-stage global biopharmaceutical company, has released its unaudited financial results for the first quarter ended March 31, 2025. The company reported a net loss from continuing operations of $2.584 million, an increase of 24% compared to the net loss of $2.080 million in the same quarter of 2024. Research and development expenses from continuing operations rose by 21%, amounting to $874,000, up from $721,000 in the prior year. General and administrative expenses also saw a significant increase of 30%, reaching $1.736 million compared to $1.334 million in the same period last year. BeyondSpring provided a corporate update, highlighting advancements in its key programs. Plinabulin has been administered to over 700 patients, demonstrating a favorable safety profile and potential efficacy in patients progressing on PD-1/L1 inhibitors, particularly in metastatic NSCLC and Hodgkin lymphoma. Moreover, SEED Therapeutics, partially owned by BeyondSpring, reported promising results for its RBM39 molecular-glue degrader, achieving durable tumor regression in Ewing sarcoma models. The company plans to pursue additional indications in collaboration with leading cancer research centers.